$7.70
▼ $-0.32
(-3.99%)
Vol 4.7M
8
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.1B
P/E
3.2
ROE
283.1%
Margin
32.1%
D/E
607.28
Beta
2.66
52W
$5–$12
Wall Street Consensus
15 analysts · Apr 20264
Strong Buy
6
Buy
2
Hold
2
Sell
1
Strong Sell
66.7%
Buy Rating
Price Chart
Similar Stocks
GLUE
Monte Rosa Therapeutics Inc
P/E 48.7
$1.0B
BCAX
Bicara Therapeutics Inc
$922.0M
OLMA
Olema Pharmaceuticals Inc
$2.0B
ZBIO
Zenas Biopharma Inc
$2.3B
TSHA
Taysha Gene Therapies Inc
$1.5B
CRVS
Corvus Pharmaceuticals Inc
$575.1M
SVRA
Savara Inc
$1.2B
AVBP
ArriVent BioPharma Inc
$830.6M
GERN
Geron Corp
$842.6M
KALV
Kalvista Pharmaceuticals Inc
$816.3M
Earnings
Beat rate: 75.0%
Next Report
May 06, 2026
EPS Estimate: $-0.24
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.24 | — | — |
| Dec 2025 | $-0.50 | $0.11 | +$0.61 |
| Sep 2025 | $-1.21 | $-1.25 | $-0.04 |
| Jun 2025 | $-0.09 | $0.62 | +$0.71 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 283.1% | 283.1% | 283.1% | 283.1% | 283.1% | 283.1% |
| P/E (TTM) | 2.41 | 3.46 | 3.70 | 3.23 | 3.14 | 3.20 |
| Net Margin | 44.5% | 39.2% | 39.2% | 39.2% | 32.1% | 32.1% |
| Gross Margin | 93.6% | 88.3% | 88.3% | 88.3% | 91.8% | 91.8% |
| D/E Ratio | 607.28 | 607.28 | 607.28 | 607.28 | 607.28 | 607.28 |
| Current Ratio | 2.36 | 2.36 | 2.36 | 2.36 | 2.27 | 2.27 |
Key Ratios
ROA (TTM)
25.5%
P/S (TTM)
1.03
P/B
11.3
EPS (TTM)
$1.77
CF/Share
$-5.39
Rev Growth 3Y
-15.9%
52W High
$11.55
52W Low
$5.01
$5.01
52-Week Range
$11.55
How does NVAX compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
NVAX valuation vs Biotechnology peers
P/E ratio
3.2
▼
83%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1.0
▼
92%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
11.3
▲
360%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
NVAX profitability vs Biotechnology peers
ROE
283.1%
▲
521%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
32.1%
▲
111%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
91.8%
▲
17%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
25.5%
▲
155%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
NVAX financial health vs Biotechnology peers
D/E ratio
607.3
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
2.3
▼
49%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
2.7
▲
174%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
NVAX fundamentals radar
NVAX
Peer median
Industry
NVAX profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio